{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:09:27Z","timestamp":1761394167541},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,4,11]],"date-time":"2012-04-11T00:00:00Z","timestamp":1334102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1756-9966-31-33","type":"journal-article","created":{"date-parts":[[2012,4,11]],"date-time":"2012-04-11T12:14:28Z","timestamp":1334146468000},"source":"Crossref","is-referenced-by-count":23,"title":["Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation"],"prefix":"10.1186","volume":"31","author":[{"given":"Antonello","family":"Vidiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Pace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Maschio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano Marco","family":"Latagliata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Anelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Piludu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine Maria","family":"Carapella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Giovinazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Marzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,11]]},"reference":[{"key":"583_CR1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","volume":"95","author":"M Lacroix","year":"2001","unstructured":"Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001, 95: 190-198. 10.3171\/jns.2001.95.2.0190.","journal-title":"J Neurosurg"},{"key":"583_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352: 987-996. 10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"key":"583_CR3","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2010.30.0582","volume":"28","author":"JK Park","year":"2010","unstructured":"Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM: Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010, 28: 3838-3843. 10.1200\/JCO.2010.30.0582.","journal-title":"J Clin Oncol"},{"key":"583_CR4","first-page":"7","volume":"19","author":"RK Jain","year":"2005","unstructured":"Jain RK: Antiangiogenic therapy for cancer: current and emerging concepts. Oncology. 2005, 19: 7-16. Review","journal-title":"Oncology"},{"key":"583_CR5","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multi- forme. J Clin Oncol. 2007, 25: 4722-4729. 10.1200\/JCO.2007.12.2440.","journal-title":"J Clin Oncol"},{"key":"583_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA: Phase II trial of single- agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009, 27: 740-745. 10.1200\/JCO.2008.16.3055.","journal-title":"J Clin Oncol"},{"key":"583_CR7","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010, 28: 1963-1972. 10.1200\/JCO.2009.26.3541.","journal-title":"J Clin Oncol"},{"key":"583_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/RLI.0b013e318229ff3e","volume":"47","author":"V Goh","year":"2011","unstructured":"Goh V, Ng QS, Miles K: Computed Tomography Perfusion Imaging for Therapeutic Assessment: Has It Come of Age as a Biomarker in Oncology?. Invest Radiol. 2011, 47: 2-4.","journal-title":"Invest Radiol"},{"key":"583_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2214\/AJR.10.4455","volume":"196","author":"CS Ng","year":"2011","unstructured":"Ng CS, Charnsangavej C, Wei W, Yao JC: Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol. 2011, 196: 569-576. 10.2214\/AJR.10.4455.","journal-title":"AJR Am J Roentgenol"},{"key":"583_CR10","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1158\/0008-5472.CAN-09-0814","volume":"69","author":"AG Sorensen","year":"2009","unstructured":"Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK: A \"vascular normalization index\" as potential mechanistic biomarker to predict survival after a single dose of cediranibin recurrent glioblastoma patients. Cancer Res. 2009, 69: 5296-5300. 10.1158\/0008-5472.CAN-09-0814.","journal-title":"Cancer Res"},{"key":"583_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1148\/radiol.10091341","volume":"55","author":"RN Sawlani","year":"2010","unstructured":"Sawlani RN, Raizer J, Horowitz SW, Shin W, Grimm SA, Chandler JP, Levy R, Getch C, Carroll TJ: Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-pilot study. Radiology. 2010, 55: 622-628.","journal-title":"Radiology"},{"issue":"29","key":"583_CR12","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1200\/JCO.2010.32.6082","volume":"10","author":"S Fellah","year":"2011","unstructured":"Fellah S, Girard N, Chinot O, Cozzone PJ, Callot V: Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. 2011, 10 (29): 308-311.","journal-title":"J Clin Oncol"},{"key":"583_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11060-008-9685-3","volume":"91","author":"S Saraswathy","year":"2009","unstructured":"Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ: Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol. 2009, 91: 69-81. 10.1007\/s11060-008-9685-3.","journal-title":"J Neurooncol"},{"key":"583_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00234-010-0808-0","volume":"53","author":"M Nowosielski","year":"2011","unstructured":"Nowosielski M, Recheis W, Goebel G, G\u00fcler O, Tinkhauser G, Kostron H, Schocke M, Gotwald T, Stockhammer G, Hutterer M: ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology. 2011, 53: 291-302. 10.1007\/s00234-010-0808-0.","journal-title":"Neuroradiology"},{"key":"583_CR15","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1093\/neuonc\/nor132","volume":"13","author":"E Hattingen","year":"2011","unstructured":"Hattingen E, Jurcoane A, B\u00e4hr O, Rieger J, Magerkurth J, Anti S, Steinbach JP, Pilatus U: Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P\/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol. 2011, 13: 1349-1363. 10.1093\/neuonc\/nor132.","journal-title":"Neuro Oncol"},{"key":"583_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/neuonc\/noq206","volume":"13","author":"BM Ellingson","year":"2011","unstructured":"Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB: Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011, 13: 401-409. 10.1093\/neuonc\/noq206.","journal-title":"Neuro Oncol"},{"key":"583_CR17","doi-asserted-by":"crossref","unstructured":"Pieper S, Lorensen B, Schroeder W, Kikinis R, The NA-MIC Kit: TK, VTK, pipelines, grids and 3D slicer as an open platform for the medical image computing community. Proceedings of the 3rd IEEE International Symposium on Biomedical Imaging: Nano to Macro. 2006, : 698-701.","DOI":"10.1109\/ISBI.2006.1625012"},{"key":"583_CR18","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1259\/bjr\/38457938","volume":"84","author":"S Masunaga","year":"2011","unstructured":"Masunaga S, Liu Y, Tanaka H, Sakurai Y, Suzuki M, Kondo N, Maruhashi A, Ono K: Reducing intratumor acute hypoxia through bevacizumabtreatment, referring to the response of quiescent tumor cells and metastatic potential. Br J Radiol. 2011, 84: 1131-1138. 10.1259\/bjr\/38457938.","journal-title":"Br J Radiol"},{"key":"583_CR19","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1245\/s10434-011-1570-1","volume":"18","author":"AC Yopp","year":"2011","unstructured":"Yopp AC, Schwartz LH, Kemeny N, Gultekin DH, G\u00f6nen M, Bamboat Z, Shia J, Haviland D, D'Angelica MI, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR: Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol. 2011, 18: 2192-2199. 10.1245\/s10434-011-1570-1.","journal-title":"Ann Surg Oncol"},{"key":"583_CR20","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1073\/pnas.1014480108","volume":"108","author":"O Keunen","year":"2011","unstructured":"Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP: Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci. 2011, 108: 3749-3754. 10.1073\/pnas.1014480108.","journal-title":"Proc Natl Acad Sci"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-31-33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-9966-31-33\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-9966-31-33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T03:34:32Z","timestamp":1548214472000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/1756-9966-31-33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,11]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["583"],"URL":"https:\/\/doi.org\/10.1186\/1756-9966-31-33","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,11]]},"article-number":"33"}}